CN113039207A - 人源化抗人pd-l1单克隆抗体及其制备方法和用途 - Google Patents

人源化抗人pd-l1单克隆抗体及其制备方法和用途 Download PDF

Info

Publication number
CN113039207A
CN113039207A CN201980075384.4A CN201980075384A CN113039207A CN 113039207 A CN113039207 A CN 113039207A CN 201980075384 A CN201980075384 A CN 201980075384A CN 113039207 A CN113039207 A CN 113039207A
Authority
CN
China
Prior art keywords
seq
variable region
chain variable
human
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980075384.4A
Other languages
English (en)
Other versions
CN113039207B (zh
Inventor
殷刘松
周铁林
方卓
米艳玲
吴瑃辰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Jinsirui Science and Technology Biology Corp
Original Assignee
Nanjing Jinsirui Science and Technology Biology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Jinsirui Science and Technology Biology Corp filed Critical Nanjing Jinsirui Science and Technology Biology Corp
Publication of CN113039207A publication Critical patent/CN113039207A/zh
Application granted granted Critical
Publication of CN113039207B publication Critical patent/CN113039207B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明涉及一种人源化抗人PD‑L1单克隆抗体及其制备方法和用途。本发明提供的人源化抗人PD‑L1单克隆抗体对PD‑L1具有高亲和性、高特异性，能够刺激T细胞分泌细胞因子，特异地解除PD‑L1的免疫负调节作用，并且这种抗体的作用不是通过直接阻断PD‑1与PD‑L1相互作用实现的，呈现了新的免疫检查点活性调节机制。因而，本发明提供的功能性人源化抗人PD‑L1单克隆抗体，可通过调节PD‑L1信号通路来激活T细胞，进而实现肿瘤免疫治疗的目的。

Description

PCT国内申请，说明书已公开。

Claims (21)

  1. PCT国内申请，权利要求书已公开。
CN201980075384.4A 2018-11-16 2019-11-15 人源化抗人pd-l1单克隆抗体及其制备方法和用途 Active CN113039207B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018113669356 2018-11-16
CN201811366935 2018-11-16
PCT/CN2019/118799 WO2020098785A1 (zh) 2018-11-16 2019-11-15 人源化抗人pd-l1单克隆抗体及其制备方法和用途

Publications (2)

Publication Number Publication Date
CN113039207A true CN113039207A (zh) 2021-06-25
CN113039207B CN113039207B (zh) 2022-10-28

Family

ID=70730658

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980075384.4A Active CN113039207B (zh) 2018-11-16 2019-11-15 人源化抗人pd-l1单克隆抗体及其制备方法和用途

Country Status (5)

Country Link
US (1) US20220073618A1 (zh)
EP (1) EP3882269A4 (zh)
CN (1) CN113039207B (zh)
TW (1) TW202020159A (zh)
WO (1) WO2020098785A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114380913A (zh) * 2022-03-24 2022-04-22 上海济煜医药科技有限公司 一种全人源抗pd-l1抗体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017220989A1 (en) * 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
CN108239149A (zh) * 2016-12-25 2018-07-03 南京传奇生物科技有限公司 高亲和力、高特异性、多抗原识别表位的具有更高功能性的抗人pd-l1抗体
CN108752476A (zh) * 2016-03-04 2018-11-06 四川科伦博泰生物医药股份有限公司 一种pdl-1抗体、其药物组合物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
JP7082055B2 (ja) * 2015-12-22 2022-06-07 ノバルティス アーゲー 抗癌治療における組み合わせ使用のためのメソテリンキメラ抗原受容体（ｃａｒ）およびｐｄ－ｌ１阻害剤に対する抗体
CN105968200B (zh) * 2016-05-20 2019-03-15 瑞阳(苏州)生物科技有限公司 抗人pd-l1人源化单克隆抗体及其应用
JP7267921B2 (ja) * 2017-01-06 2023-05-02 クレシェンド・バイオロジックス・リミテッド プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体
WO2019129211A1 (en) * 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Antibodies and variants thereof against pd-l1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108752476A (zh) * 2016-03-04 2018-11-06 四川科伦博泰生物医药股份有限公司 一种pdl-1抗体、其药物组合物及其用途
WO2017220989A1 (en) * 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
CN108239149A (zh) * 2016-12-25 2018-07-03 南京传奇生物科技有限公司 高亲和力、高特异性、多抗原识别表位的具有更高功能性的抗人pd-l1抗体

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114380913A (zh) * 2022-03-24 2022-04-22 上海济煜医药科技有限公司 一种全人源抗pd-l1抗体及其应用
CN114380913B (zh) * 2022-03-24 2022-06-21 上海济煜医药科技有限公司 一种全人源抗pd-l1抗体及其应用

Also Published As

Publication number Publication date
EP3882269A1 (en) 2021-09-22
TW202020159A (zh) 2020-06-01
US20220073618A1 (en) 2022-03-10
CN113039207B (zh) 2022-10-28
WO2020098785A1 (zh) 2020-05-22
EP3882269A4 (en) 2022-10-12

Similar Documents

Publication Publication Date Title
EP3341020B1 (en) Pd-l1 ("programmed death-ligand 1") antibodies
RU2711141C2 (ru) Антитела против pd-1
JP2024023225A (ja) 抗体－サイトカイングラフト化タンパク質及び癌の治療における使用方法
KR20210116207A (ko) 인간 ClAUDIN 18.2에 결합하는 항체 및 그 용도
JP2020521481A (ja) Ｆｌｔ３に特異的な抗体およびその使用
TW201039845A (en) Treatment with a humanized anti-EGFR igG1 antibody and irinotecan
EP4001308A1 (en) Anti-tigit antibodies and application thereof
US20210332137A1 (en) Combination therapy for cancer
WO2021170020A1 (en) Antibodies binding il4r and uses thereof
WO2019076277A1 (zh) 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途
CN113166248B (zh) 人源化抗人ox40单克隆抗体及其制备方法和用途
CN112513088B (zh) 抗ox40抗体、其抗原结合片段及其医药用途
MX2014007644A (es) Anticuerpos antagonistas del receptor de hormona de crecimiento humana y metodos para su uso.
KR20230144596A (ko) 항 cd112r 항체 및 그의 용도
US20230030597A1 (en) Methods of treating cancer by the use of pd-1 axis inhibitors and anti-periostin antibodies
CN113039207B (zh) 人源化抗人pd-l1单克隆抗体及其制备方法和用途
CN112513084B (zh) 人源化抗人ctla4单克隆抗体及其制备方法和用途
CN115515980A (zh) C19 c38双特异性抗体
CN114929741A (zh) 针对lif的抗体及其用途
CN116829591A (zh) 针对cd112r的抗体及其用途
TW202130661A (zh) 抗ox40抗體及其用途
CN114761434A (zh) Pd-1抗体及其制备方法与应用
TW202028226A (zh) Ｉｌ－１５蛋白複合物聯合ｐｄ－ｌ１抗體用於治療腫瘤疾病的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20210625

Assignee: Nanjing vigorous Biotechnology Co.,Ltd.

Assignor: NANJINGJINSIRUI SCIENCE & TECHNOLOGY BIOLOGY Corp.

Contract record no.: X2023990000155

Denomination of invention: Humanized anti-human PD-L1 monoclonal antibody and its preparation method and use

Granted publication date: 20221028

License type: Exclusive License

Record date: 20230116

EE01 Entry into force of recordation of patent licensing contract